{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"submitter":["Schuster NM"],"funding":["Academic Senate, University of California, Riverside","NCATS NIH HHS","NCCIH NIH HHS","NINDS NIH HHS","National Institutes of Health","Migraine Research Foundation","NIH HHS","Academic Senate, University of California, San Diego"],"pubmed_abstract":["<h4>Objective</h4>To assess the efficacy of cannabis for the treatment of acute migraine.<h4>Background</h4>Preclinical and retrospective studies suggest cannabinoids may be effective in migraine treatment. However, there have been no randomized clinical trials examining the efficacy of cannabinoids for acute migraine.<h4>Methods</h4>In this randomized, double-blind, placebo-controlled, crossover trial, adults with migraine treated up to four separate migraine attacks, one each with vaporized (1) 6% Δ9-tetrahydrocannabinol (THC) (THC-dominant), (2) 11% cannabidiol (CBD) (CBD-dominant), (3) 6% THC + 11% CBD, and (4) placebo cannabis flower in a randomized order. Washout period between treated migraine attacks was ≥1 week. The primary endpoint was pain relief, and secondary endpoints were pa"],"journal":["Headache"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12872409"],"repository":["biostudies-literature"],"pubmed_title":["Vaporized cannabis versus placebo for acute migraine: A randomized, double-blind, placebo-controlled crossover trial."],"pmcid":["PMC12872409"],"funding_grant_id":["UL1TR001442","UL1 TR001442","R00 AT009466","UL1 TR000100","U24 NS115714","OT2 NS122680"],"pubmed_authors":["Schuster NM","Liu L","Wallace MS","Marcotte TD","Sexton M","Buse DC","Lee E"],"additional_accession":[]},"is_claimable":false,"name":"Vaporized cannabis versus placebo for acute migraine: A randomized, double-blind, placebo-controlled crossover trial.","description":"<h4>Objective</h4>To assess the efficacy of cannabis for the treatment of acute migraine.<h4>Background</h4>Preclinical and retrospective studies suggest cannabinoids may be effective in migraine treatment. However, there have been no randomized clinical trials examining the efficacy of cannabinoids for acute migraine.<h4>Methods</h4>In this randomized, double-blind, placebo-controlled, crossover trial, adults with migraine treated up to four separate migraine attacks, one each with vaporized (1) 6% Δ9-tetrahydrocannabinol (THC) (THC-dominant), (2) 11% cannabidiol (CBD) (CBD-dominant), (3) 6% THC + 11% CBD, and (4) placebo cannabis flower in a randomized order. Washout period between treated migraine attacks was ≥1 week. The primary endpoint was pain relief, and secondary endpoints were pa","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Dec","modification":"2026-07-15T13:57:17.125Z","creation":"2026-07-05T03:12:22.359Z"},"accession":"S-EPMC12872409","cross_references":{"pubmed":["41469488"],"doi":["10.1111/head.70025"]}}